Why Estrella Immunopharma, Inc.’s (ESLA) Stock Is Up 5.79%
As of Friday, May 01, Estrella Immunopharma, Inc.’s ESLA share price has surged by 5.79%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Commentary & Analysis
Why Estrella Immunopharma, Inc.’s (ESLA) Stock Is Down 8.77%
As of Friday, April 24, Estrella Immunopharma, Inc.’s ESLA share price has dipped by 8.77%, which has investors questioning if this is right time to buy.Michael Rose
Why Estrella Immunopharma, Inc.’s (ESLA) Stock Is Up 8.16%
As of Tuesday, April 21, Estrella Immunopharma, Inc.’s ESLA share price has surged by 8.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Estrella Immunopharma, Inc.’s (ESLA) Stock Is Up 5.24%
As of Friday, April 10, Estrella Immunopharma, Inc.’s ESLA share price has surged by 5.24%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Estrella Immunopharma, Inc.’s (ESLA) Stock Is Down 6.77%
As of Thursday, April 09, Estrella Immunopharma, Inc.’s ESLA share price has dipped by 6.77%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ESLA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $32.0 | $292.6 | 12% |
|
| Shares Out (Mil) | 43.0 | 54.4 | 44% |
|
| Institutional Ownership | 50.6% | 93.2% | 35% |
|
| Float (Mil) | 14.1 | 40.2 | 24% |
|
| Beta | 0.89 | 0.94 | 53% |
|
| Avg Daily Volume (000s) | 29 | 544 | 23% |
|
| Price Change (52-week) |
(18.5%) | 59.7% | 29% |
|
| Growth | ESLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (79.7%) | (10.1%) | 3% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.080) | ($0.290) | ($0.320) | |
| Month Ago EPS | ($0.080) | ($0.290) | ($0.320) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | na | ($0.390) | ($0.320) | |
| Year/Year Chg | 48.1% | (18.3%) | (12.7%) | |
| Financials | ESLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($43) | 29% |
|
| EPS (TTM) | ($0.250) | ($1.400) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $32 | $164 | 14% |
|
| Valuation | ESLA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ESLA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (416.7%) | (47.5%) | 1% |
|
| ROE | 148.1% | (55.0%) | 97% |
|
| Liabilities to Assets | 507.3% | 29.6% | 100% |
|
| F-Score | 2 | 3 | 7% |
|
Estrella Immunopharma, Inc. did not pass any screens on 8/21/2026.
